14.06.2016 • NewsDede WillamscapacityPharmaceutical

Carbogen Amcis Expanding Swiss Capacity

(c) Westend61/Getty Images
(c) Westend61/Getty Images

Carbogen Amcis, a Swiss company specialized in process development and manufacturing of Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, is expanding its   operations in Bubendorf, Switzerland, to take account of a “significant and continuous increase in customers’ demand for additional capacity, including demand for labs and small scale development.”

The company has purchased a 3,360 m2 multi-story building on 5,200 m² of land and will convert it to its own specifications. When operations begin in January 2017, the premises will house laboratory, production, storage and office areas and provide a set of clean-room GMP compliant suites.

Stephan Fritschi, vice president Operations at Carbogen Amcis, said the immediate proximity to the company’s current headquarters and its larger scale production site in Bubendorf, Switzerland, is “ideal,” as it will allow a significantly expansion of laboratory capacity for highly potent development and small scale production as well as analytical support.

In the near future, the company said it plans to introduce a number of additional capabilities including commercial manufacture of ADCs and additional Cat 4 (ng OEL) development capacity.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Free Virtual Event

Sustainability in Bioprocessing
Bioprocess Forum

Sustainability in Bioprocessing

Join us to explore hot topics in sustainable bioprocessing like the industrial potential of enzymatic synthesis, innovative biocatalysis techniques, and the use of digital twins in bioprocessing.